Predicting drug interaction potential with a physiologically based pharmacokinetic model: A case study of telithromycin, a time-dependent CYP3A inhibitor

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 700-708

  Vieira, M L T ^a,b   Zhao, P ^a   Berglund, E G ^a,c   Reynolds, K S ^a   Zhang, L ^a   Lesko, L J ^a   Huang, S M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; MIDAZOLAM; TELITHROMYCIN;

AREA UNDER THE CURVE; ARTICLE; ENZYME INHIBITION; HUMAN; MODEL; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME;

CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FORECASTING; HUMANS; KETOLIDES; MALE; MIDAZOLAM; MODELS, BIOLOGICAL; MODELS, CHEMICAL;

EID: 84862776856     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.305     Document Type: Article

References (37)

1. Shi, J., Montay, G. & Bhargava, V.O. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin. Pharmacokinet. 44, 915-934 (2005). (Pubitemid 41252842)
2. Aventis Pharmaceuticals Ltd. Ketek (telithromycin) Tablets. Drug approval package.http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/21-144-Ketek. cfm. Accessed Dec 2010 Accessed Dec 2010.
3. US Food and Drug Administration. Center for Drug Evaluation and Research (CDER) . Draft guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling (2012). Accessed February 2012.
4. Zhang, L., Zhang, Y.D., Zhao, P. & Huang, S.M. Predicting drug-drug interactions: an FDA perspective. AAPS J. 11, 300-306 (2009).
5. Sanofi-Aventis Canada Inc. Product Monograph-KETEK? (telithromycin filmcoated tablets, 400 mg) Anti-bacterial Agent . Accessed Dec 2010.
6. Huang, S.M. et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48, 662-670 (2008).
7. Pachot, J.I., Botham, R.P., Haegele, K.D. & Hwang, K. Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci. 6, 1-12 (2003). (Pubitemid 37207237)
8. Perret, C. et al. Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy 48, 217-223 (2002).
9. Bhargava, V., Lenfant, B., Perret, C., Pascual, M.H., Sultan, E. & Montay, G. Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand. J. Infect. Dis. 34, 823-826 (2002). (Pubitemid 36124481)
10. Namour, F., Wessels, D.H., Pascual, M.H., Reynolds, D., Sultan, E. & Lenfant, B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob. Agents Chemother. 45, 170-175 (2001). (Pubitemid 32039110)
11. Zhao, P. et al. Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. J. Clin. Pharmacol. 52 (1 suppl.), 91S-108S (2012).
12. Kanamitsu, S., Ito, K., Green, C.E., Tyson, C.A., Shimada, N. & Sugiyama, Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm. Res. 17, 419-426 (2000). (Pubitemid 30395296)
13. Kato, M. et al. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm. Res. 25, 1891-1901 (2008).
14. Zhao, P. et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J. Clin. Pharmacol. 49, 351-359 (2009).
15. Gibson, C.R., Bergman, A., Lu, P., Kesisoglou, F., Denney, W.S. & Mulrooney, E. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica. 39, 637-648 (2009).
16. Jamei, M. et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225-237 (2009).
17. Lukacova, V., Woltosz, W.S. & Bolger, M.B. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J. 11, 323-334 (2009).
18. Rostami-Hodjegan, A. & Tucker, G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140-148 (2007). (Pubitemid 46745341)
19. Howgate, E.M., Rowland-Yeo, K., Proctor, N.J., Tucker, G.T. & Rostami-Hodjegan, A. Incorporation of inter-individual variability into the prediction of in vivo drug clearance from in vitro data. Drug Metab. Rev. 37, 99 (2005).
20. Rowland-Yeo, K., Walsky, R.L., Jamei, M., Rostami-Hodjegan, A. & Tucker, G.T. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur. J. Pharm. Sci. 43, 160-173 (2011).
21. Fowler, S. & Zhang, H. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J. 10, 410-424 (2008).
22. Obach, R.S. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr. Opin. Drug Discov. Devel. 12, 81-89 (2009).
23. Tucker, G.T., Houston, J.B. & Huang, S.M. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. Br. J. Clin. Pharmacol. 52, 107-117 (2001). (Pubitemid 32862777)
24. Aventis Pharmaceuticals Ltd. Ketek™ (telithromycin) Briefing document for the FDA Anti-Infective Drug Products Advisory Committee Meeting . Accessed Dec 2010.
25. Grimm, S.W. et al. The conduct of in vitro studies to address timedependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab. Dispos. 37, 1355-1370 (2009).
26. Sindrup, S.H., Brosen, K. & Gram, L.F. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharm. Ther. 51, 288-295 (1992).
27. Venkatakrishnan, K. & Obach, R.S. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab. Dispos. 33, 845-852 (2005). (Pubitemid 40686639)
28. Quinney, S.K., Zhang, X., Lucksiri, A., Gorski, J.C., Li, L. & Hall, S.D. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab. Dispos. 38, 241-248 (2010).
29. US Food and Drug Administration. Drug development and drug interactions: possible models for decision-making . Accessed Oct 2011.
30. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
31. Pang, S.K. & Rowland, M. Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in perfused rat liver in situ preparation. J. Pharmacokinet. Biopharm. 5, 681-699 (1977). (Pubitemid 8253672)
32. Johnson, T.N., Tucker, G.T., Tanner, M.S. & Rostami-Hodjegan, A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 11, 1481-1493 (2005). (Pubitemid 43072624)
33. Mayhew, B.S., Jones, D.R. & Hall, S.D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28, 1031-1037 (2000). (Pubitemid 30660356)
34. Yang, J. et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab. 9, 384-394 (2008).
35. Cantalloube, C., Bhargava, V., Sultan, E., Vacheron, F., Batista, I. & Montay, G. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int. J. Antimicrob. Agents 22, 112-121 (2003). (Pubitemid 36970169)
36. Edlund, C., Alv, G., Barkholt, L., Vacheron, F. & Nord, C.E. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J. Antimicrob. Chemother. 46, 741-749 (2000).
37. Lippert, C., Gbenado, S., Qiu, C., Lavin, B. & Kovacs, S.J. The bioequivalence of telithromycin administered orally as crushed tablets versus tablets swallowed whole. J. Clin. Pharmacol. 45, 1025-1031 (2005). (Pubitemid 41192361)